Celgene Corporation's Apremilast Succeeds in Phase 3 Psoriasis Trial
Published: Mar 05, 2013
Based on standard Psoriasis Area and Severity Index, this drug named apremilast is effective in the case of one third of patients and is showing perfect 75% reduction in symptoms. This is much greater result compared to the similar drug named PASI-75 as stated by the company in Miami Beach, Florida.
National Psoriasis Foundation reports shows that this is a dermatological disease which causes red and scalpy patches on skin and around 7.5million people of U.S suffer because of this disease. According to an analyst Mr. Mark Schoenebaum, the market for this treatment is estimated to be around $10billion worldwide. In his research report, Schoenebaum mentioned that this medicine is best with best in class safety profile.
Celgene has also tested the same drug for the treatment of psoriatic arthritis and it is thinking to apply the same medicine for the treatment. The company is trying the medicine on ankylosing. spondylitis, Behcet’s disease and rheumatoid arthritis. According to a survey, Apremilast has a potential to generate revenues of $1.14billion by 2017.
Company showed the results that 59% of patients are treated effectively to reduce 50% of the symptoms. This new Celgene drug is oral and suppresses the enzyme called PDE4 which causes the skin patches. Other drugs such as Amgen Inc (NASDAQ:AMGN), Pfizer Inc (NYSE:PFE), Abbvie Inc (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) are given by injection and works under different approaches.
Celgene Corp (NASDAQ:CELG) is up by 2.28% closing at $105.62
Amgen Inc (NASDAQ:AMGN) is up by 1.13% closing at $92.58
Pfizer Inc (NYSE:PFE) is up by 0.07% closing at $27.39
Abbvie Inc (NYSE:ABBV) is up by 2.41% closing at $37.81
Johnson & Johnson (NYSE:JNJ) is up by 0.78% closing at $76.70